Sector News

Santen establishes UK subsidiary

November 5, 2014
Life sciences
Japanese drugmaker Santen has set up shop in the UK to help push its recently acquired glaucoma franchise from Merck & Co into the market.
 
The group said it has established a UK subsidiary to promote products such as Saflutan and Cosopt – purchased from Merck back in May for $600 million plus royalties – and help strengthen its footprint in Europe.
 
“The establishment of our own subsidiary in the UK is an important step in achieving our long term corporate vision to become a specialised pharmaceutical company with a global presence”, said Masamichi Sato, Head of Santen European Group and President of Santen Holding EU BV.
 
The move will allow the group to provide its complete portfolio of products throughout Europe, and the launch of commercial teams in other European countries such as Spain, Portugal or Benelux “is expected within the next few months,” he added.
 
By Selina McKee
 
Source: Pharma Times
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach